Related Experiment Video
Updated: May 14, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Omega-3 in antiarrhythmic therapy : cons position
1Division of Internal Medicine, University of Bologna, Sant'Orsola Malpighi Hospital, Via Massarenti 9, 40138, Bologna, Italy. claudio.borghi@unibo.it
Summary
Omega-3 fatty acids
Area of Science:
- Cardiovascular research
- Clinical pharmacology
- Nutritional science
Background:
- The clinical impact of omega-3 (n-3 polyunsaturated fatty acids) on cardiovascular disease outcomes, particularly its antiarrhythmic effects and mechanisms, remains unclear.
- Epidemiological studies suggest reduced sudden cardiac death incidence with omega-3-rich diets or fish consumption over the past 15 years.
- Proposed antiarrhythmic mechanisms involve modulating myocyte ion channels and reducing excitability in ischemic myocardial tissue, though experimental results vary.
Purpose of the Study:
- To evaluate the association between omega-3 fatty acids and clinical outcomes in cardiovascular disease patients.
- To clarify the antiarrhythmic effects and mechanisms of omega-3 fatty acids.
- To assess the role of omega-3 in preventing sudden cardiac death and arrhythmias.
Main Methods:
- Review of epidemiological studies and clinical trials evaluating omega-3 intake or supplementation in cardiovascular patients.
- Analysis of experimental studies investigating the electrophysiological effects of omega-3 on cardiac myocytes.
- Examination of meta-analyses and specific randomized clinical trials, including GISSI-Prevenzione.
Main Results:
- While some meta-analyses show a reduction in cardiac death, evidence for omega-3 preventing sudden cardiac death is controversial and inconsistent across studies.
- Omega-3 may play a role in preventing cardiovascular mortality via multiple mechanisms, warranting investigation alongside other cardiovascular drugs.
- Omega-3 appears more effective in preventing atrial tachyarrhythmias, such as atrial fibrillation, than ventricular arrhythmias.
Conclusions:
- The antiarrhythmic effect of omega-3 fatty acids is not definitively established.
- Further research is essential to elucidate the precise role of omega-3 in preventing cardiac mortality, especially compared to arrhythmic death.
- Investigating omega-3's interaction with other cardiovascular medications is crucial for understanding its overall clinical benefit.
Related Concept Videos
01:22Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
01:12Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...